Sivik Global Healthcare LLC Has $5.06 Million Position in GW Pharmaceuticals PLC- (GWPH)
Sivik Global Healthcare LLC boosted its position in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 500.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,000 shares of the biopharmaceutical company’s stock after buying an additional 25,000 shares during the quarter. GW Pharmaceuticals PLC- makes up 1.9% of Sivik Global Healthcare LLC’s holdings, making the stock its 26th biggest position. Sivik Global Healthcare LLC’s holdings in GW Pharmaceuticals PLC- were worth $5,057,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in GWPH. Virtu Financial LLC grew its position in GW Pharmaceuticals PLC- by 71.9% during the fourth quarter. Virtu Financial LLC now owns 7,574 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 3,169 shares during the period. Sequoia Wealth Management LLC grew its position in shares of GW Pharmaceuticals PLC- by 80.6% in the fourth quarter. Sequoia Wealth Management LLC now owns 4,425 shares of the biopharmaceutical company’s stock valued at $431,000 after purchasing an additional 1,975 shares during the period. JGP Global Gestao de Recursos Ltda. acquired a new stake in shares of GW Pharmaceuticals PLC- in the fourth quarter valued at about $242,000. Quantamental Technologies LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the fourth quarter valued at about $78,000. Finally, Horrell Capital Management Inc. grew its position in shares of GW Pharmaceuticals PLC- by 33.3% in the fourth quarter. Horrell Capital Management Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 100 shares during the period. Institutional investors own 79.60% of the company’s stock.
NASDAQ:GWPH opened at $184.80 on Wednesday. The company has a current ratio of 7.81, a quick ratio of 7.19 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $5.40 billion, a PE ratio of -17.50 and a beta of 2.75. GW Pharmaceuticals PLC- has a twelve month low of $90.14 and a twelve month high of $196.00.
Several analysts have recently issued reports on the stock. BidaskClub lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. Morgan Stanley reiterated a “buy” rating on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, April 9th. Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $193.00 target price on the stock in a research report on Thursday, April 11th. Oppenheimer upgraded shares of GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $162.00 to $234.00 in a research report on Tuesday, May 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $196.00 target price (up previously from $193.00) on shares of GW Pharmaceuticals PLC- in a research report on Monday, March 18th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $205.40.
In other news, CFO Scott M. Giacobello sold 4,224 shares of the firm’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $14.52, for a total value of $61,332.48. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Volker Knappertz sold 12,144 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $14.64, for a total transaction of $177,788.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,021,432 shares of company stock worth $44,883,255. Insiders own 5.50% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/sivik-global-healthcare-llc-has-5-06-million-position-in-gw-pharmaceuticals-plc-gwph/3018804.html.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Featured Story: Federal Reserve
Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.